Molika Ashford

Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.

Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.

The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.

A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.

The company believes that it has threaded the needle in terms of providing the maximum of necessary information to clinicians, while maintaining a rapid turnaround time.

The authors of a commentary said they view recent study results as informative, though limited, regarding the test's performance in prostate cancer.

Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.

Sophia sponsored a meeting gathering early adopters, pharma partners, and others to discuss the recently launched MSK-ACCESS, and soon-to-launch MSK-IMPACT kits.

Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.

Researchers described the process they took to adapt their methodology for improved BRCA variant classification through ClinGen in a new study this week.